Approaches and Challenges for Biosensors for Acute and Chronic Heart Failure.
Sariye Irem KayaAhmet CetinkayaGoksu OzcelikaySeyda Nur SamanciSibel Ayşıl ÖzkanPublished in: Biosensors (2023)
Heart failure (HF) is a cardiovascular disease defined by several symptoms that occur when the heart cannot supply the blood needed by the tissues. HF, which affects approximately 64 million people worldwide and whose incidence and prevalence are increasing, has an important place in terms of public health and healthcare costs. Therefore, developing and enhancing diagnostic and prognostic sensors is an urgent need. Using various biomarkers for this purpose is a significant breakthrough. It is possible to classify the biomarkers used in HF: associated with myocardial and vascular stretch (B-type natriuretic peptide (BNP), N-terminal proBNP and troponin), related to neurohormonal pathways (aldosterone and plasma renin activity), and associated with myocardial fibrosis and hypertrophy (soluble suppression of tumorigenicity 2 and galactin 3). There is an increasing demand for the design of fast, portable, and low-cost biosensing devices for the biomarkers related to HF. Biosensors play a significant role in early diagnosis as an alternative to time-consuming and expensive laboratory analysis. In this review, the most influential and novel biosensor applications for acute and chronic HF will be discussed in detail. These studies will be evaluated in terms of advantages, disadvantages, sensitivity, applicability, user-friendliness, etc.
Keyphrases
- low cost
- acute heart failure
- heart failure
- public health
- cardiovascular disease
- liver failure
- healthcare
- left ventricular
- drug induced
- risk factors
- label free
- respiratory failure
- gene expression
- aortic dissection
- gold nanoparticles
- atrial fibrillation
- hepatitis b virus
- metabolic syndrome
- coronary artery disease
- cardiac resynchronization therapy
- cardiovascular events
- health insurance